An expert subcommittee was formed consisting of members of the AAN and AES to update the 2004 evidence-based guidelines on epilepsy treatment with AEDs.
Studies that have evaluated the use of VNS in children, including those as young as 6 months old, and have generally concluded that it is well tolerated and improves quality of life.
The NDA for IM/IV Captisol-Enabled Fosphenytoin has been accepted for review and given a Prescription Drug Fee User Act date, by the FDA.
Potentially modifiable risk factors in midlife are associated with the risk of developing late-onset epilepsy.
Cognitive and linguistic deficits have been cited as risk factors for psychiatric comorbidity in pediatric epilepsy, along with family factors such as parenting style and quality of the parent-child relationship.
Claims data spanning 4 years were obtained from a pediatric accountable care organization.
The safety and efficacy of clobazam monotherapy in patients with new-onset focal or generalized seizures was investigated in a new Cochrane systematic review.
The efficacy was reported to be significantly higher in patients who had taken benzodiazepines.
Causes of death in patients with epilepsy were assessed to determine the presence of cardiac pathology.
The FDA has approved an abbreviated New Drug Application for Vigadrone, the generic alternative to Sabril powder for oral solution.
Investigators sought to examine whether seizures are capable of causing changes in serotonin levels in the peripheral circulation.
Next-generation sequencing can improve treatment efficacy and reduce hospitalization in children with drug-resistant epilepsy.
In individuals who can adequately access healthcare appointments, medications, and other treatments, the combination of driving restrictions and sparse or nonexistent public transportation options interferes with daily living and their overall quality of life.
Since MRI and EEG risk factors were retrospectively reviewed, the study was unable to analyze the temporal seizure burden or the volume of MRI injury, both of which may have provided greater insights into outcomes.
The primary efficacy outcome was achieved in a higher percentage of patients in the exposure range of 9 to 15 ng/mL compared with patients in the 3 to 7 ng/mL and >7 to 9 ng/mL ranges.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
The sNDA included data from Study 311 (N=180), an ongoing, open-label, multicenter trial with an extension phase that evaluated the safety, tolerability, and exposure-efficacy relationship of Fycompa oral suspension as adjunctive therapy in children (4 to 11 years) with inadequately controlled POS or PGTC seizures.
At 8 years, the cumulative rate of any hospitalization or emergency department visit for seizure was higher among patients with stroke vs the general population.
The results of this study should help reassure and encourage women with epilepsy without a prior diagnosis of infertility or an associated disorder who are seeking pregnancy.
The effects of short-term VPA exposure on placental compound carrier expression were examined in this study.
Cannabidiol plus conventional antiepileptics reduces drop seizure frequency in the Lennox-Gastaut syndromeMay 24, 2018
Amongst adults and children with the Lennox-Gastaut syndrome, addition of cannabidiol to a conventional antiepileptic regimen reduced drop seizure frequency compared to placebo treated patients.
A majority of participants (67%) had reported seeing a neurologist or epilepsy specialist in the past year, with younger adults comprising a higher percentage of these participants.
The expanded approval was supported by extrapolated efficacy data from placebo-controlled studies in adults with partial-onset seizures.
The investigators concluded that these findings should help to identify targets for intervention to reduce the overall time to treatment in this population.
The approval was based on a 12-week, double-blind, placebo-controlled study (N=295) in pediatric patients 4-17 years of age.
The approval is specifically for bilateral anterior thalamic nucleus stimulation and is based on results from the SANTE study (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy).
Although most adults with epilepsy report taking epilepsy medication, less than half of those report having their seizures controlled.
Researchers evaluated the use of genetic screening to identify individuals who are at risk for carbamazepine-induced cutaneous adverse drug reactions.
Investigators conducted a population-based study to assess risk and cause of unnatural mortality in individuals with epilepsy.
Clinicians should conduct a medical evaluation as soon as suspicious symptoms are reported and discontinue lamotrigine if HLH is suspected.
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- High Treatment Adherence and Quality of Life Observed With Fingolimod
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Insurance Status Tied to Higher Self-Perceived Poor/Fair Health
- Early Treatment Failure More Likely With Carbamazepine vs Lamotrigine in Epilepsy
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Concurrent Non-Motor Functions Strongly Associated With Parkinson Disease
- Feeling Young May Be Reflected in Brain Structure